BioInformant Worldwide, LLC, has recently released the market intelligence report titled “The Complete 2012-13 Induced Pluripotent Stem Cell (iPSC) Industry Report.”
The market intelligence report presents financial metrics for the Induced Pluripotent Stem Cell Industry, as well as key findings discovered from surveying a global audience of iPSC researchers (293 respondents). It reveals iPSC product and industry trends with five-year projections; informs about iPSC grants, patents and publications; identifies profitable opportunities for producers of iPSC products, and presents critical insights into future tools that iPSC scientists will require. In addition, it clearly denotes preferred species for iPSC research, analyzes the competitive environment for iPSC research products, and breaks down market share by competitor – providing an overall view of the iPSC product landscape.
iPSCs are adult stem cells that have been transformed into embryotic-like stem cells through the manipulation of gene expression and similar methods. Despite some initial concerns, induced pluripotent stem cells (iPSC) are now sold by more than half (53.4%) of U.S. research product companies and 38.7% of research product companies worldwide.
"It is clear that iPSC products are in high demand within the scientific community. Currently, it is difficult for stem cell research product suppliers, like BD BioSciences, Life Technologies, and others, to know what products iPSC scientists will demand in 2013 and beyond. The needs of scientists are constantly changing, so this market intelligence report reveals profitable opportunities for providers of iPSC research products to pursue,” says BioInformant.
For the past five decades, stem cell research has provided insights to the inner workings of the body and cell regeneration. “Therapeutic applications of iPSCs represent the future of medicine," says BioInformant. The scientific community believes that one day stem cell research will assist in finding viable treatments for crippling diseases such as Parkinson’s, Alzheimer’s, spinal cord injuries and more.
“This is a must-read industry report for research supply companies to optimally position themselves to sell iPSC research products. This is a lucrative and rapidly expanding market,” explains BioInformant. “The study will help you understand your key strengths relative to the competition.”
The study is backed by a 100% money back guarantee, to ensure that the strategies, findings and tools are found helpful.